DB:72C1

Stock Analysis Report

Executive Summary

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally.


Snowflake Analysis

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Eiger BioPharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 72C1's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.9%

72C1

-2.3%

DE Biotechs

-0.2%

DE Market


1 Year Return

-5.3%

72C1

8.4%

DE Biotechs

13.7%

DE Market

Return vs Industry: 72C1 underperformed the German Biotechs industry which returned 8.4% over the past year.

Return vs Market: 72C1 underperformed the German Market which returned 13.7% over the past year.


Shareholder returns

72C1IndustryMarket
7 Day0.9%-2.3%-0.2%
30 Day-12.8%-3.2%0.3%
90 Day2.8%6.3%3.7%
1 Year-5.3%-5.3%8.6%8.4%17.2%13.7%
3 Year5.2%5.2%44.5%42.9%15.4%5.3%
5 Yearn/a13.0%10.6%21.3%4.7%

Price Volatility Vs. Market

How volatile is Eiger BioPharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Eiger BioPharmaceuticals undervalued compared to its fair value and its price relative to the market?

4.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 72C1's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 72C1's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 72C1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 72C1 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 72C1's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 72C1 is overvalued based on its PB Ratio (4x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Eiger BioPharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

60.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 72C1 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 72C1 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 72C1 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 72C1's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 72C1's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 72C1's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Eiger BioPharmaceuticals performed over the past 5 years?

-30.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 72C1 is currently unprofitable.

Growing Profit Margin: 72C1 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 72C1 is unprofitable, and losses have increased over the past 5 years at a rate of -30.8% per year.

Accelerating Growth: Unable to compare 72C1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 72C1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 72C1 has a negative Return on Equity (-97.45%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Eiger BioPharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 72C1's short term assets ($114.4M) exceed its short term liabilities ($16.7M).

Long Term Liabilities: 72C1's short term assets ($114.4M) exceed its long term liabilities ($31.6M).


Debt to Equity History and Analysis

Debt Level: 72C1's debt to equity ratio (42.1%) is considered high.

Reducing Debt: Insufficient data to determine if 72C1's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 72C1 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 72C1's debt is covered by short term assets (assets are 3.8x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 72C1 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 72C1 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -33.7% each year.


Next Steps

Dividend

What is Eiger BioPharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 72C1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 72C1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 72C1's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 72C1's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 72C1's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

David Cory (55yo)

3.9yrs

Tenure

US$2,091,742

Compensation

Mr. David A. Cory, R.Ph, MBA, is Business Founder of Eiger Biopharmaceuticals, Inc. and has been its Chief Executive Officer and President since March 22, 2016. Mr. Cory served as the Chief Executive Offic ...


CEO Compensation Analysis

Compensation vs Market: David's total compensation ($USD2.09M) is above average for companies of similar size in the German market ($USD625.18K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
David Cory
Business Founder3.9yrsUS$2.09m0.40% $1.1m
Jeffrey Glenn
Founder3.9yrsUS$110.11k0.75% $2.0m
James Shaffer
Chief Business Officer3.9yrsUS$948.59k0.059% $158.9k
Eldon Mayer
Executive VP & Chief Commercial Officer0.08yrsUS$348.56k0.10% $275.4k
Sriram Ryali
Chief Financial Officer1.2yrsno data0.0057% $15.4k
Ingrid Choong
Vice President of Operations1.1yrsno datano data
Stephana Patton
General Counsel0.9yrsno data0.016% $44.1k
Rich Franco
Senior Vice President of Progeria Program0.8yrsno datano data
Colin Hislop
Senior Vice President of Clinical & Development Operations0yrsno datano data

1.1yrs

Average Tenure

55yo

Average Age

Experienced Management: 72C1's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
David Cory
Business Founder3.9yrsUS$2.09m0.40% $1.1m
Jeffrey Glenn
Founder3.9yrsUS$110.11k0.75% $2.0m
Thomas Dietz
Chairman3.9yrsUS$135.67k0.098% $264.4k
David Apelian
Director2.7yrsUS$2.49mno data
Amit Sachdev
Independent Director0.8yrsno datano data
Stanley Rockson
Scientific Advisor0yrsno datano data
Evan Loh
Independent Director2.4yrsUS$105.49kno data
Christine Murray
Independent Director1.1yrsno datano data
Tracey McLaughlin
Scientific Advisor0yrsno datano data

2.7yrs

Average Tenure

55yo

Average Age

Experienced Board: 72C1's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 72C1 insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 81.6%.


Top Shareholders

Company Information

Eiger BioPharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eiger BioPharmaceuticals, Inc.
  • Ticker: 72C1
  • Exchange: DB
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$291.246m
  • Listing Market Cap: US$269.869m
  • Shares outstanding: 24.50m
  • Website: https://www.eigerbio.com

Number of Employees


Location

  • Eiger BioPharmaceuticals, Inc.
  • 2155 Park Boulevard
  • Palo Alto
  • California
  • 94306
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EIGRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDMar 2016
72C1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2016

Biography

Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company’s lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection. Its product candidates also include Lambda, which targets type III IFN receptors; Lonafarnib for the treatment of progeria and progeroid laminopathies; Avexitide for treating post-bariatric hypoglycemia; and Ubenimex, an oral, small-molecule inhibitor of leukotriene A4 hydrolase for treating lymphedema. The company was founded in 2008 and is headquartered in Palo Alto, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 22:39
End of Day Share Price2020/02/20 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.